Article Text
Statistics from Altmetric.com
Commentary on: OpenUrlCrossRefPubMed.
Context
Helicobacter pylori infection is the main cause of several gastric diseases including gastritis, peptic ulcer and gastric cancer. Traditional anti-H. pylori treatments fail in up to 20–30% of naive patients requiring intervention. Failed attempts may cause the acquisition of resistance by H. pylori or the selection of resistant/resilient strains, hindering second-line treatments.
One of the most recommended second-line regimens is triple therapy with levofloxacin (LT); however, its efficacy has never been optimal, with an estimated pooled eradication rate of 79%.1 In order to improve these results, Liou and colleagues performed a randomised trial comparing LT with a levofloxacin containing sequential therapy (LS).
Methods
The study was …
Footnotes
Contributors AGM drafted the manuscript, and JPG critically reviewed it.
Competing interests AGM has received funds for a scientific oral presentation in one event promoted by Allergan. JPG has received funds to promote research from – and/or has provided advisory and education activities to – Almirall, Allergan, AstraZeneca, Casen Recordati, Nycomed.
Provenance and peer review Commissioned; internally peer reviewed.